SULT1B1 Antibody (N-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | O43704 |
---|---|
Other Accession | NP_055280 |
Clone Names | 3112608 |
Gene ID | 27284 |
---|---|
Other Names | Sulfotransferase family cytosolic 1B member 1, ST1B1, Sulfotransferase 1B1, 282-, Sulfotransferase 1B2, ST1B2, Thyroid hormone sulfotransferase, SULT1B1, ST1B2, SULT1B2 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP2605a was selected from the N-term region of human SULT1B1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | SULT1B1 |
---|---|
Synonyms | ST1B2 {ECO:0000303|PubMed:9443824}, SULT |
Function | Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of dopamine, small phenols such as 1-naphthol and p-nitrophenol and thyroid hormones, including 3,3'-diiodothyronine, triidothyronine (T3) and reverse triiodothyronine (rT3) (PubMed:28084139, PubMed:9443824, PubMed:9463486). May play a role in gut microbiota-host metabolic interaction. O-sulfonates 4-ethylphenol (4-EP), a dietary tyrosine- derived metabolite produced by gut bacteria. The product 4-EPS crosses the blood-brain barrier and may negatively regulate oligodendrocyte maturation and myelination, affecting the functional connectivity of different brain regions associated with the limbic system (PubMed:35165440). |
Cellular Location | Cytoplasm |
Tissue Location | Highly expressed in the liver, peripheral blood leukocytes, colon (mucosal lining), small intestine (jejunum) and spleen. A lesser expression was observed in the lung, placenta and thymus. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Cytosolic sulfotransferase (ST) enzymes catalyze the sulfate conjugation of many drugs, xenobiotic compounds, hormones, and neurotransmitters. Sulfotransferases such as SULT1B1 catalyze the biotransformation of a large number of endogenous compounds such as neurotransmitters, steroids, bile acids, and thyroid hormones, as well as drugs and xenobiotics. SULT1B1 contains a binding site for the sulfate donor, 3-prime-phosphoadenosine 5-prime-phosphosulfate, and a cysteine residue conserved in the ST1 gene family of sulfotransferases. SULT1B1 shares between 51.5% and 56.3% amino acid sequence identity with members of the phenol sulfotransferase gene family. Northern blot analysis detects 4 SULT1B1 transcripts between 79 kb and 13 kb expressed at highest levels in liver, peripheral blood leukocytes, colon, small intestine, and spleen. Lower expression is detected in lung, placenta, and thymus, and no expression is detected in other tissues. Recombinant rat and human SULT1B1, expressed in E. coli, catalyze sulfation of p-nitrophenol, 3,3-prime,5-triiodothyronine (T3), and dopamine, but not of beta-estradiol and dehydroepiandrosterone. SULT1B1 shows higher affinities for formation of T3 sulfate than do the phenol sulfotransferases ST1A3 (SULT1A1) or ST1A5. Bacterially-expressed SULT1B1 sulfates small phenols such as 1-naphthol and p-nitrophenol and thyroid hormones, including 3,3-prime-diiodothyronine, triiodothyronine, reverse triiodothyronine, and thyroxine. No activity is detected against several sterols or dopamine.
References
Fujita, K., et al., J. Biochem. 122: 1052-1061 (1997).Wang, J., et al., Molec. Pharm. 53: 274-282 (1998).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.